Results 81 to 90 of about 21,372 (208)

Guillain–Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu, Ping‐Hsuan Lin, Chia‐Hsuan Chiu, Hui‐Hua Hsiao   +3 more
wiley   +1 more source

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia
: The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax.
Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids   +13 more
doaj   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Haematologica, 2018
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia ...
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan   +47 more
doaj   +1 more source

Venetoclax for the treatment of patients with chronic lymphocytic leukemia

, 2017
Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis in chronic lymphocytic leukemia (CLL) cells ...
Matthew S. Davids, Jennifer Crombie
core   +1 more source

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium

British Journal of Haematology, EarlyView.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Estelle Borgne, Anne‐Charlotte de Grande, Audrey Sarry, Ziyad Acheaibi, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Marie‐Anne Hospital, Martin Carré, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz   +22 more
wiley   +1 more source

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review [PDF]

Yinyu Zhao,1,2 Nan Guo,1,3 Yidan Zhu,1,2 Jingyuan Shang,4 Jiali Chen,1,3 Xingxian Luo,1 Yi Liu,1 Xiaohong Zhang,1 Lin Huang1 1Department of Pharmacy, Peking University People’s Hospital, Beijing, People’s Republic of China; 2School of Pharmaceutical ...
Guo N, Liu Y, Zhu Y, Chen J, Zhang X, Shang J, Luo X, Huang L, Zhao Y   +8 more
core  

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

, 2020
BACKGROUND: Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
Porkka, Kimmo, Turgut M., Leber, Brian, Koller E., Porkka K., Potluri J., Döhner, Hartmut, Pratz, Keith W, Konopleva M., DiNardo C. D., Letai, Anthony, Yamamoto, Kazuhito, Lemoli R. M., Leber B., DiNardo, Courtney D, Esteve, Jordi, Lavie, David, Esteve J., Pejsa, Vlatko, Thirman, Michael J, Wei, Andrew H, Konopleva, Marina, Garcia J. S., Turgut, Mehmet, Pullarkat V., Illes A., Jang J. -H., Pratz K. W., Hajek R., Wang, Jianxiang, Dohner H., Yamamoto K., Thirman M. J., Yoon, Sung-Soo, Wang J., Garcia, Jacqueline S, Fenaux P., Havelange, Violaine, Pejsa V., Illés, Árpád, Yeh S. -P., Pullarkat, Vinod, Fenaux, Pierre, Letai A., Potluri, Jalaja, Hájek, Roman, Jonas B. A., Hong, Wan-Jen, Hong W. -J., Koller, Elizabeth, Zhou Y., Yoon S. -S., Jang, Jun-Ho, Lavie D., Havelange V., Zhou, Ying, Yeh, Su-Peng, Jonas, Brian A, Lemoli, Roberto M, Wei A. H.   +59 more
core   +1 more source

P042 | PU.1 as master regulator of acute myeloid leukemia venetoclax resistance

Haematologica
Introduction. Venetoclax-based therapies have improved outcomes in acute myeloid leukemia (AML), especially in elderly or unfit patients. However, resistance remains a major limitation.
Alessandro Ferrando
doaj  

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

Haematologica
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs).
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan   +22 more
doaj   +1 more source